放疗联合替莫唑胺在高级别脑胶质瘤患者中的疗效观察(1)
摘要：目的 探讨放疗联合替莫唑胺在高级别脑胶质瘤患者中的临床效果及对毒副反应发生率的影响。方法 选择2015年6月～2018年2月我院收治的高级别脑胶质瘤患者68例作为研究对象，采用随机数字表分为对照组和观察组，各34例。两组均行手术治疗，对照组术后给予放疗治疗，观察组在对照组基础上联合替莫唑胺治疗，3个月治疗后完成患者效果评估，比较两组炎症反应及对毒副反应发生率的影响。结果 观察组治疗后3个月HGF、TNF-a及IL-17水平，均低于对照组(P<0.05);两组治疗期间胃肠反应、骨髓抑制、肝功能损害、放射性脑坏死及头铺溃疡发生率均无统计学意义(P>0.05)。结论 将放疗联合替莫唑胺用于高级别脑胶质瘤患者中有助于降低炎症反应，未增加毒副反应发生率。
关键词：放疗;替莫唑胺;高级别脑胶质瘤;炎症反应;毒副反应
中图分类号：R739.41 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.03.053
, http://www.100md.com
文章编号：1006-1959(2019)03-0160-02
Abstract：Objective To investigate the clinical effect of radiotherapy combined with temozolomide in patients with high grade glioma and its influence on the incidence of toxic side effects.Methods From June 2015 to February 2018，68 patients with high grade glioma in our hospital were selected as study objects and were randomly divided into control group and observation group with 34 cases each.The two groups were treated by operation， the control group was treated with radiotherapy after operation， and the observation group was treated with temozolamide on the basis of the control group. After 3 months of treatment， the effect of the two groups was evaluated. The inflammatory reaction and the incidence of side effects were compared between the two groups.Results The levels of HGF，TNF-a and IL-17 in the observation group were lower than those in the control group 3 months after treatment(P<0.05).There was no significant difference in gastrointestinal reaction，bone marrow suppression， liver function damage， radiation brain necrosis and scalp ulcer between the two groups(P>0.05).Conclusion Radiotherapy combined with temozolidomide in high grade glioma patients can reduce inflammatory reaction， but does not increase the incidence of side effects.
, 百拇医药
Key words：Radiotherapy;Temozolamide;High-grade glioma;Inflammatory reaction;Toxicity
高级别脑胶质瘤(high-grade glioma)属于低分化胶质瘤，是一种长期的恶性肿瘤，患者生存预后较差[1]。目前，临床上对于高级别胶质瘤病因尚不清楚，普遍认为与先天的遗传、环境的致癌因素等有关，影响患者健康、生活。手术治疗是高级别脑胶质瘤患者中常用的治疗方法，虽然能切除病灶组织，延长患者寿命，但是术后复发率及局部转移率较高，影响患者预后[2]。调强放疗是三维适形放疗的一种，是放疗的新型方式。替莫唑胺是新一代化疗药物，生物利用度较高，容易透过血脑屏障，能作用于细胞周期的各个时期。目前放疗聯合替莫唑胺在高级别胶质瘤患者中的应用及毒副反应的影响研究较少[3]。本研究选择我院收治的68例高级别脑胶质瘤患者作为研究对象，拟探讨放疗联合替莫唑胺在高级别脑胶质瘤患者中的临床效果及对毒副反应发生率的影响，现报道如下。, 百拇医药(王春城)
关键词：放疗;替莫唑胺;高级别脑胶质瘤;炎症反应;毒副反应
中图分类号：R739.41 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.03.053
, http://www.100md.com
文章编号：1006-1959(2019)03-0160-02
Abstract：Objective To investigate the clinical effect of radiotherapy combined with temozolomide in patients with high grade glioma and its influence on the incidence of toxic side effects.Methods From June 2015 to February 2018，68 patients with high grade glioma in our hospital were selected as study objects and were randomly divided into control group and observation group with 34 cases each.The two groups were treated by operation， the control group was treated with radiotherapy after operation， and the observation group was treated with temozolamide on the basis of the control group. After 3 months of treatment， the effect of the two groups was evaluated. The inflammatory reaction and the incidence of side effects were compared between the two groups.Results The levels of HGF，TNF-a and IL-17 in the observation group were lower than those in the control group 3 months after treatment(P<0.05).There was no significant difference in gastrointestinal reaction，bone marrow suppression， liver function damage， radiation brain necrosis and scalp ulcer between the two groups(P>0.05).Conclusion Radiotherapy combined with temozolidomide in high grade glioma patients can reduce inflammatory reaction， but does not increase the incidence of side effects.
, 百拇医药
Key words：Radiotherapy;Temozolamide;High-grade glioma;Inflammatory reaction;Toxicity
高级别脑胶质瘤(high-grade glioma)属于低分化胶质瘤，是一种长期的恶性肿瘤，患者生存预后较差[1]。目前，临床上对于高级别胶质瘤病因尚不清楚，普遍认为与先天的遗传、环境的致癌因素等有关，影响患者健康、生活。手术治疗是高级别脑胶质瘤患者中常用的治疗方法，虽然能切除病灶组织，延长患者寿命，但是术后复发率及局部转移率较高，影响患者预后[2]。调强放疗是三维适形放疗的一种，是放疗的新型方式。替莫唑胺是新一代化疗药物，生物利用度较高，容易透过血脑屏障，能作用于细胞周期的各个时期。目前放疗聯合替莫唑胺在高级别胶质瘤患者中的应用及毒副反应的影响研究较少[3]。本研究选择我院收治的68例高级别脑胶质瘤患者作为研究对象，拟探讨放疗联合替莫唑胺在高级别脑胶质瘤患者中的临床效果及对毒副反应发生率的影响，现报道如下。, 百拇医药(王春城)